Entellus Medical, Inc. (NASDAQ:ENTL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, October 31st.
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
Several other equities research analysts have also commented on the stock. Canaccord Genuity reissued a “hold” rating and set a $17.00 price objective on shares of Entellus Medical in a research note on Tuesday, October 17th. Piper Jaffray Companies reissued a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a research note on Tuesday, August 22nd. Finally, BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $21.17.
Entellus Medical (NASDAQ ENTL) opened at $15.90 on Tuesday. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $20.34. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92.
COPYRIGHT VIOLATION NOTICE: “Entellus Medical, Inc. (NASDAQ:ENTL) Stock Rating Lowered by Zacks Investment Research” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/entellus-medical-inc-entl-downgraded-to-hold-at-zacks-investment-research/1746023.html.
In other news, VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total value of $40,020.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Stephen R. Paidosh sold 25,000 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total transaction of $438,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,150 shares of company stock valued at $1,740,652. 7.70% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of ENTL. Swiss National Bank lifted its position in Entellus Medical by 98.9% during the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after purchasing an additional 8,800 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Entellus Medical by 5.6% during the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares during the last quarter. Vanguard Group Inc. lifted its position in Entellus Medical by 77.8% during the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after purchasing an additional 185,833 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Entellus Medical by 87.0% in the 1st quarter. Geode Capital Management LLC now owns 97,417 shares of the medical technology company’s stock worth $1,344,000 after acquiring an additional 45,310 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Entellus Medical in the 1st quarter worth about $290,000. Hedge funds and other institutional investors own 70.12% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with our FREE daily email newsletter.